Shire to Buy Biotech Firm Dyax

Ireland-based and London-listed drugmaker Shire has agreed what is being called a “defensive” deal to buy US biotech firm Dyax, which has a breakthrough drug said to threaten one of its own.

Initally, Shire will pay $5.9 billion, or $37.30 per share, for the company in an all-cash deal. Dyax shareholders potentially could receive an additional $4 per share – adding $646 million to the total – if the development drug, DX-2930, is approved by regulatory authorities for treatment of hereditary angioedema by 2019.

The drug was fast-tracked by the US Food and Drug Administration (FDA) in July following completion of early-stage trials, in which it was shown to reduce by more than 90% the number of attacks of the potentially life-threatening hereditary disease that attacks the immune system and causes swelling.

The deal with the biotech firm, which would allow Shire to take control of phase 3 trials with DX-2930, comes on the heels of a stalemate in Shire’s attempt to acquire Baxalta, a recent spin-off from Baxter International. That company’s management thus far has resisted the takeover bid worth more than $30 billion.

Analysts are said to have warned that DX-2930 could cannibalize sales of Shire’s Cinryze, a drug to treat the same ailment, acquired with the $4.2 billion purchase of ViroPharma last year.

Shire CEO Flemming Ornskov said he likes to buy firms with trials at stage 3 level in order to shape the tests and “create the best profile for the product.” Ornskov has projected a launch of DX-2930 by 2018 and potential peak sales of $2 billion annually.

With Dyax, Shire also will gain access to the biotech firm’s Kalibitor, a post-attack treatment for hereditary angioedema with annual sales of more than $68 million.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.